Advancing peptide therapeutics through extracellular matrix biology

Apmonia Therapeutics is a French-Belgian biotechnology company developing innovative peptide therapeutics targeting extracellular matrix signaling and protein-protein interactions involved in cancer progression.

Founded in 2019 as a spin-off of the French National Centre for Scientific Research (CNRS) and the University of Reims Champagne-Ardenne, Apmonia combines scientific research, peptide discovery and drug development expertise to advance new therapeutic approaches.

Researcher at a microscope in the laboratory

From academic research to therapeutic innovation

Founded in 2019, Apmonia Therapeutics builds on research conducted within the MEDyC laboratory (UMR CNRS 7369), a joint research unit of CNRS and the University of Reims Champagne-Ardenne.

The company’s scientific foundations lie in extracellular matrix biology and the role of protein-protein interactions in disease mechanisms. This research led to the development of TAX2 (AP-01), a first-in-class cyclic peptide targeting the TSP-1/CD47 interaction, now being evaluated in an ongoing Phase 1/2a clinical trial in patients with advanced solid tumors.

Today, Apmonia is building on this scientific foundation to develop a pipeline of peptide therapeutics in oncology and cardiovascular disease.

Explore our pipeline
3D model of TAX2 (AP-01), a first-in-class cyclic peptide

A team combining scientific
and biotech expertise

Apmonia brings together expertise in research, biotechnology, pharmaceutical development and business strategy to advance its therapeutic programs.

Its executive team is supported by a strategic board and a Scientific and Clinical Advisory Board, bringing complementary perspectives to the company’s scientific and clinical development.

Executive leadership

  • Albin Jeanne
    Albin JEANNECEO / CSOFounder and scientific leader of Apmonia Therapeutics.LinkedIn

Strategic Board

  • Aurore Andre
    Aurore ANDREMS, MBA
  • Nissim Darvish
    Nissim DARVISHMD, PhD
  • Alexandre Koressios
    Alexandre KORESSIOSMSc
  • Abderrahim Lachgar
    Abderrahim LACHGARPhD
  • Stéphane Loze
    Stéphane LOZEPhD
  • Jérôme Majoie
    Jérôme MAJOIEMBA
  • Virginie Miath
    Virginie MIATHMSc
  • Julie Rachline
    Julie RACHLINEPhD

Scientific and Clinical Advisory Board

  • Stéphane Dedieu
    Stéphane DEDIEUPhD, Chair of the Scientific and Clinical Advisory Board, CNRS and University of Reims
  • Alexandra Leary
    Alexandra LEARYMD, PhD, Gustave Roussy Institute
  • Armand Bensussan
    Armand BENSUSSANPhD, Saint-Louis Hospital and Jean Godinot Institute
  • Olivier Bouché
    Olivier BOUCHÉMD, PhD, Reims Hospital
  • Liliana Schaefer
    Liliana SCHAEFERMD, PhD, University of Frankfurt/Main and Thomas Jefferson University, Philadelphia

A scientific vision focused on patients

Our ambition is to develop new therapeutic approaches by targeting extracellular mechanisms involved in disease progression.

By combining fundamental research with translational development, Apmonia aims to turn discoveries in extracellular matrix biology into therapeutic candidates with the potential to address unmet medical needs.

We work alongside scientific, clinical and pharmaceutical partners to advance our programs and bring new therapeutic possibilities closer to patients.